Pivotal readout
Mazdutide Gains China Reimbursement
Innovent says mazdutide has been included in China's 2026 national reimbursement drug list for glycemic control in adults with type 2 diabetes, with the revised list effective January 1, 2027. The company cites DREAMS phase 3 trials showing glycemic and weight benefits, including a 48% composite response rate in DREAMS-3 versus 21% with semaglutide. In obesity studies, mazdutide was associated with weight reductions of 14.84% at 48 weeks in GLORY-1 and 20.1% at 60 weeks in GLORY-2.
Written by Gosset from public sources. Source types: News article. Sources are available to Gosset users. Log in to see them.
